Merck & Co. has entered a $349 million deal with Variational AI to apply generative AI technology in designing and optimizing small molecule drug candidates against two undisclosed therapeutic targets. This partnership exemplifies the pharmaceutical industry’s increasing reliance on AI-driven platforms to enhance drug discovery efficiency and improve clinical success rates. Variational AI’s ability to generate fine-tuned molecular designs accelerates the pipeline for innovative treatments.